Abstract
Objective: To explore simultaneous improvements in the Psoriasis Area and Severity Index (PASI) or body surface area affected by psoriasis (BSA) and quality of life (QOL) in pediatric patients with moderate to severe psoriasis treated with secukinumab through 52 weeks.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
